| 2019-01-03 07:40:22|
DMAC 07:40 01/03 01/03/19
DiaMedica Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started DiaMedica Therapeutics with a Buy rating and a $9 price target. The analyst believes its unique stroke and kidney treatment validated in China sets up DiaMedica as a high reward opportunity, while positive Phase 2 results could move the stock above his price target.